论文部分内容阅读
目的介绍新辅助治疗(neoadjuvant therapy)联合经肛切除术在治疗T2～3期直肠癌中的应用和进展。方法收集国内、外关于新辅助治疗联合经肛切除术治疗T2～3期直肠癌的文献并进行分析和综述。结果对于经过严格选择的T2～3期直肠癌患者,采用新辅助治疗联合经肛手术可以有效地提高保肛率,减少并发症的发生。与仅进行手术而未行新辅助治疗的患者相比,复发率由17%～62%降到0～20%。结论经过严格选择的T2～3期直肠癌患者可从新辅助治疗联合经肛手术中受益。
Objective To introduce the application and progress of neoadjuvant therapy combined with anal resection in the treatment of T2 ~ 3 rectal cancer. Methods The domestic and foreign literature on neoadjuvant therapy combined with anal resection for T2 ~ 3 rectal cancer was collected and analyzed and summarized. Results For patients with T2 ~ 3 rectal cancer who underwent rigorous treatment, neoadjuvant therapy combined with transanal surgery can effectively improve the rate of anus retention and reduce the incidence of complications. The recurrence rate was reduced from 17% to 62% to 0 to 20% compared with patients who underwent neoadjuvant surgery who underwent surgery alone. Conclusions Tightly selected T2 ~ 3 rectal cancer patients may benefit from neoadjuvant therapy combined with anal surgery.